Relmada extends key man provisions in esmethadone license to Dec 31, 2027

RELMADA THERAPEUTICS, INC.

Amendment No. 2 extends the 'Key Man' termination-protection period from Dec 31, 2022 to Dec 31, 2027.
Licensor may terminate license if CEO Sergio Traversa is fired without cause or his role is materially reduced.
License covers esmethadone (REL-1017) for psychiatric use; no other terms of the license were changed.
Extension locks in CEO-linked protections for an additional five years through 2027.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

RELMADA THERAPEUTICS, INC. amended License Agreement with Drs. Charles E. Inturrisi and Paolo Manfredi (effective 2022-12-27).

Action: amendment
Agreement: license
Counterparty: Drs. Charles E. Inturrisi and Paolo Manfredi
Effective: 2022-12-27

Exact text from the filing

On December 27, 2022, the Licensor and the Company entered into an Amendment No. 2 to the License Agreement extending the duration of the “Key Man” provisions of the License Agreement

View on SEC.gov

119 material agreements filed in the last 30 days. Browse all material agreements →

RELMADA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001213900-22-083290

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.